0.04 ml semaglutide FDA approves obesity drug that

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes [1] [2]

doi: 10.1177/2040622315603951 161 SiebenhaarFMeldeAMagerlMZuberbierTChurchMKMaurerM

And since they can target multiple signaling pathways simultaneously, dual agonist drugs may also lead to improved metabolic action

using high-molecular-weight PEG for competitive inhibition and designing complement inhibitors to block the related immune modulation effects [219]

Funding This review received no grant from any funding agency in the public, commercial, or not-for-profit sectors